In addition, our data further demonstrate that ARID1A depletion enhances the sensitivity of SCLC cell lines to the BET inhibitor JQ1, and the compound BRD-K98645985 exerts antitumor effects against SCLC through targeted inhibition of ARID1A while also synergizing with JQ1 to suppress SCLC growth. Here, ARID1A is linked to small cell lung carcinoma.